MEET THE PEOPLE BEHIND PHYLOGICA

About Us

Phylogica is developing next generation intracellular biological therapeutics, including its own preclinical Myc, STAT 5 and YB1 oncology inhibitor payloads, using its proprietary best-in-class cell penetrating FPPs.

Phylogica is developing next generation intracellular biological therapeutics, including its own preclinical oncology payloads, using its proprietary best-in-class cell Functional Penetrating Phylomers® (FPPs),  with quantifiably demonstrable superior endosomal escape.   Phylogica’s FPPs are also being used in a number of external collaborations in modular combination with a wide range of biologic payloads developed by partners for a range of diverse disease targets.   These technologies are derived from Phylogica’s Phylomer® peptide libraries.

Phylogica’s Intracellular Pipeline

Phylogica’s libraries contain hundreds of billions of distinct peptides known as Phylomer peptides, which represent a rich source of biologically active drug leads. These natural peptides are based on expressed sequences of protein fragments that are encoded by the genes of evolutionary diverse microbes and they thus represent a new class of biological therapeutics, which is protected by granted international patents.

Phylomer peptides display exceptional structural stability, specificity and affinity, thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies.

The quality of Phylomer libraries has been validated through partnerships with major pharmaceutical companies that include Genentech, MedImmune, Pfizer and Janssen Biotech (the pharmaceutical division of Johnson & Johnson) and Roche.  Phylogica offers access to its intracellular delivery technology for diverse protein/nucleic acid cargoes.

The Company has a strong and broad intellectual property portfolio around its Phylomer peptide libraries and associated technology including its proprietary technology for more efficient intracellular delivery of biologics.

Phylogica originated from a collaboration between the Telethon Institute for Child Health Research (Perth, Western Australia) and the Fox Chase Cancer Centre (Philadelphia, USA), and was spun out in 2001. The Company listed on the Australian Stock Exchange (ASX:PYC) in March 2005.

Phylogica is headquartered in Perth, Australia.